Belite Bio outlines February 12, 2027 PDUFA date for Tinlarebant in Stargardt disease following FDA priority review acceptance (NASDAQ:BLTE)
· seekingalpha.com
Belite Bio (BLTE) Q2 2026 earnings call: Tinlarebant NDA accepted with priority review (PDUFA Feb 12, 2027), cash runway, key risks—read now.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...